Nitric oxide and viral cardiomyopathy.
Finkel
M S
MS
D000818:Animals; D009202:Cardiomyopathies / Q000378:metabolism* / Q000821:virology; D003384:Coxsackievirus Infections / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism / Q000494:pharmacology; D016189:Dystrophin / Q000378:metabolism; D029822:Enterovirus B, Human / Q000201:enzymology; D006801:Humans; D051379:Mice; D009205:Myocarditis / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism* / Q000494:pharmacology; D020030:Nitric Oxide Donors / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D011817:Rabbits; D014664:Vasodilation / Q000187:drug effects; D014764:Viral Proteins; D014779:Virus Replication / Q000187:drug effects
D016207:Cytokines; D016189:Dystrophin; D020030:Nitric Oxide Donors; D014764:Viral Proteins; D009569:Nitric Oxide; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D003546:Cysteine Endopeptidases; C057400:picornain 2A, Picornavirus; D006152:Cyclic GMP